Medication evidence profile
Levomepromazine
Clinical overview
Levomepromazine has public medication-list entries in JARS 2025, Yamada-ABS 2023, BAAS 2019, Swe-ABS 2023, GABS 2018, KABS 2020 open validation supplement, and CALS 2022 Table 4. These are 7 separate source versions, each with its own evidence and definitions.
Source-specific scores
| Source | Score |
|---|---|
| JARS | 2 |
| Yamada-ABS | 3 |
| BAAS | 2 |
| Swe-ABS | 3 |
| GABS | 3 |
| KABS | 2 |
| CALS | 3 |
How to read this: 0 means the source explicitly assigned zero. “Not listed” means the source did not provide a score for this medication. Scores from different scales are not averaged.
Other names used in the sources
Levomepromazine (methotrimeprazine), Levomepromazine/methotrimeprazine, Methotrimeprazine, methotrimeprazine
How to interpret the evidence
7 of 7 public source versions contain an explicit medication-list entry for levomepromazine.
The recorded values differ across the source rows for levomepromazine. Scale methods, definitions, source eras, evidence types and identity handling can differ; the numbers alone do not establish the reason for this medication’s disagreement.
None of the public rows in this profile is an explicit zero. An unlisted source still supplies no value.
Source labels and provenance · 7 observations
- Japanese Anticholinergic Risk Scale (JARS) 2025 English translation
Source label: Levomepromazine/methotrimeprazine. Published value: 2.
Source version: JARS-2025
Source location: RC4 source recovery; recovery_scope=primary_table_complete; ATC=N05AA02
Observation: JARS_2025_R0029; rating state: published_rating. - Yamada Pharmacological Anticholinergic Burden Scale 2023
Source label: Levomepromazine. Published value: 3.
Source version: YAMADA-ABS-2023
Source location: RC4 source recovery; recovery_scope=primary_nonzero_complete
Observation: YAMADA_ABS_2023_R0091; rating state: published_rating. - Brazilian Anticholinergic Activity Scale 2019
Source label: Levomepromazine. Published value: 2.
Source version: BAAS-2019
Source location: RC4 source recovery; recovery_scope=primary_table_complete
Observation: BAAS_2019_R0052; rating state: published_rating. - Swedish Anticholinergic Burden Scale 2023
Source label: Levomepromazine. Published value: 3.
Source version: SWE-ABS-2023
Source location: RC4 source recovery; recovery_scope=primary_final_nonzero_complete
Observation: SWE_ABS_2023_R0096; rating state: published_rating. - German Anticholinergic Burden Score 2018
Source label: Levomepromazine. Published value: 3.
Source version: GABS-2018
Source location: RC4 source recovery; recovery_scope=primary_nonzero_complete
Observation: GABS_2018_R0138; rating state: published_rating. - KABS 2019 scale - 2020 open validation supplement
Source label: Levomepromazine; Methotrimeprazine. Published value: 2.
Source version: KABS-2020-validation-supplement
Source location: Additional file 1; category Antipsychotics; table row 41
Observation: KABS2020_SUPP_0183; rating state: published_validation_supplement_rating. - CALS 2022 - primary final Table 4
Source label: Levomepromazine. Published value: 3.
Source version: CALS-2022-primary-table4
Source location: Table 4; literal capture row 21; displayed table row 3; displayed column 7
Observation: CALS2022_T4_0021; rating state: published_final_table_rating.
What this page does not establish
- All public source versions represented by this release have an entry for this medication. Coverage of this selected source set does not establish complete evidence for every population or formulation.
- Do not infer route equivalence from canonical grouping; use source label/table annotations.
- These source records do not estimate an individual’s probability of harm or establish whether to start, stop or change a medication. Ordinal source scores are not averaged into a UnifiedACB score.
References
- Mizokami F, Mizuno T, Taguchi R, et al. Development of the Japanese Anticholinergic Risk Scale: English translation of the Japanese article. Geriatr Gerontol Int. 2025;25(1):5-13. doi:10.1111/ggi.15001. Open source
- Yamada S, Mochizuki M, Chimoto J, Futokoro R, Kagota S, Shinozuka K. Development of a pharmacological evidence-based anticholinergic burden scale for medications commonly used in older adults. Geriatr Gerontol Int. 2023;23(7):558-564. doi:10.1111/ggi.14619. Open source
- Nery RT, Reis AMM. Development of a Brazilian anticholinergic activity drug scale. Einstein (Sao Paulo). 2019;17(2):eAO4435. doi:10.31744/einstein_journal/2019AO4435. Open source
- Rube T, Ecorcheville A, Londos E, Modig S, Johansson P. Development of the Swedish anticholinergic burden scale (Swe-ABS). BMC Geriatr. 2023;23(1):518. doi:10.1186/s12877-023-04225-1. Open source
- Kiesel EK, Hopf YM, Drey M. An anticholinergic burden score for German prescribers: score development. BMC Geriatr. 2018;18(1):239. doi:10.1186/s12877-018-0929-6. Open source
- Suh Y, Ah YM, Han E, et al. Dose response relationship of cumulative anticholinergic exposure with incident dementia: validation study of Korean anticholinergic burden scale. BMC Geriatr. 2020;20(1):265. doi:10.1186/s12877-020-01671-z. Open source
- Ramos H, Moreno L, Pérez-Tur J, Cháfer-Pericás C, García-Lluch G, Pardo J. CRIDECO Anticholinergic Load Scale: an updated anticholinergic burden scale. Comparison with the ACB Scale in Spanish individuals with subjective memory complaints. J Pers Med. 2022;12(2):207. doi:10.3390/jpm12020207. Open source
Ask a follow-up
Go to your medication comparison · How UnifiedACB handles disagreement
Ask about this medication
Medication context: Levomepromazine
Ask about this medication